• Like a specialized Vertex Pharmaceuticals focused on developing innovative drugs for inflammatory and skin diseases.
• A smaller AbbVie, but concentrating on immune-mediated and dermatological conditions.
• Similar to a focused Regeneron Pharmaceuticals, but with a niche in inflammatory and skin conditions.

• Zunsemetinib (oral MK2 inhibitor): This investigational small molecule is Aclaris's lead drug candidate, currently in clinical trials for the treatment of various immuno-inflammatory diseases, including rheumatoid arthritis and psoriatic arthritis.

Aclaris Therapeutics (ACRS) is a biopharmaceutical company that develops and commercializes treatments. Its approved product, ZORYVE (roflumilast) cream, is sold through the standard pharmaceutical distribution channels. Therefore, its major customers are not individual patients but large pharmaceutical wholesale distributors.

These wholesale distributors purchase ZORYVE directly from Aclaris Therapeutics in bulk and then distribute it to retail pharmacies, hospitals, and other healthcare providers. These entities, in turn, dispense the medication to patients based on prescriptions.

The major pharmaceutical wholesale distributors that typically serve as primary customers for pharmaceutical manufacturers in the United States include:

• McKesson Corporation (Symbol: MCK)
• AmerisourceBergen Corporation (Symbol: ABC)
• Cardinal Health, Inc. (Symbol: CAH)

These companies act as critical intermediaries in the supply chain, handling a significant portion of product distribution for pharmaceutical manufacturers.

Dr. Neal Walker, Chief Executive Officer and Chair of the Board of Directors

Dr. Walker is a board-certified dermatologist and serial entrepreneur who co-founded Aclaris Therapeutics. He previously co-founded and served as CEO of Vicept Therapeutics, Inc., which was acquired by Allergan, Inc. in 2011. He also co-founded and led Octagon Research Solutions, Inc. (acquired by Accenture plc) and Trigenesis Therapeutics, Inc. (acquired by Dr. Reddy's Laboratories Inc.). Additionally, he co-founded NeXeption, LLC, a biopharmaceutical assets management company.

Kevin Balthaser, Chief Financial Officer

Mr. Balthaser has served as Aclaris' Chief Financial Officer since January 2023, having joined the company in 2017 and held various roles of increasing responsibility. Before Aclaris, he held several finance and accounting positions at Lannett Company, Inc., a publicly traded generic pharmaceutical company, where he was involved in capital market transactions and acquisitions. He began his career at PricewaterhouseCoopers LLP.

James Loerop, Chief Business Officer

Mr. Loerop has been Aclaris' Chief Business Officer since January 2022. Prior to joining Aclaris, he was Executive Vice President, Business Development and Strategic Planning at Anika Therapeutics, Inc. He also served as Chief Corporate Development Officer for Lupin Pharmaceuticals, Inc. and held senior leadership roles at Alexion Pharmaceuticals, Inc., GlaxoSmithKline, and Stiefel Laboratories, Inc., which was acquired by GSK.

Dr. David Gordon, Chief Medical Officer

Dr. Gordon joined Aclaris as Chief Medical Officer in May 2018. Before Aclaris, he spent 18 years at GlaxoSmithKline plc (GSK), where he was Senior Vice President and Head of Dermatology Research and Development. During his tenure at GSK, he led teams responsible for drug discovery through development and post-approval and successfully developed and obtained regulatory approval for drugs such as NUCALA® and BENLYSTA®.

Matthew Rothman, General Counsel and Corporate Secretary

Mr. Rothman has served as General Counsel and Corporate Secretary since November 2022. He joined Aclaris in 2018 and previously held various roles within the legal department. Before Aclaris, he was an associate in the corporate and securities group at the law firm Dechert LLP.

Bristol Myers Squibb's oral TYK2 inhibitor, Sotyktu (deucravacitinib), represents a clear emerging threat. Approved in September 2022 for moderate-to-severe plaque psoriasis and subsequently for psoriatic arthritis (PsA), Sotyktu is a new, orally administered treatment with a differentiated mechanism of action compared to Aclaris's lead candidate zunsemetinib, which is a JAK1 inhibitor being developed for psoriatic arthritis. Given the heightened regulatory scrutiny and safety warnings associated with the JAK inhibitor class, Sotyktu's distinct MOA and strong efficacy/safety profile in PsA provide a significant competitive advantage as Aclaris seeks to advance zunsemetinib into a market where a recently established, non-JAK oral therapy is already available.

Aclaris Therapeutics (symbol: ACRS) is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The addressable markets for their main product candidates are as follows:

• For product candidates targeting Atopic Dermatitis (e.g., Bosakitug (ATI-045), ATI-052, ATI-1777, ATI-2138):
  • The global atopic dermatitis market was valued at approximately USD 17 billion in 2024 and is projected to grow to USD 37 billion by 2037.
• For product candidates targeting Ulcerative Colitis (e.g., ATI-2138, which has shown activity in colitis models):
  • The global ulcerative colitis market size was valued at USD 8 billion in 2024 and is estimated to reach USD 12.5 billion by 2033.
• For product candidates targeting Crohn's Disease (e.g., ATI-2138, which has shown activity in colitis models, and other potential inflammatory bowel disease treatments):
  • The global Crohn's disease market was valued at USD 11.9 billion in 2024 and is projected to reach USD 17.8 billion by 2035.
• For product candidates targeting Rheumatoid Arthritis (e.g., ATI-2138, which has shown activity in arthritis models, and Aclaris develops JAK inhibitors relevant to this disease):
  • The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033.
• For product candidates targeting Psoriasis (as JAK inhibitors are a treatment class for psoriasis, and Aclaris has JAK inhibitor candidates):
  • The global psoriasis drugs market size was estimated at USD 21.12 billion in 2024 and is projected to reach USD 39.11 billion by 2030.
• For product candidates targeting Vitiligo (as JAK inhibitors are an advancement in vitiligo treatment, and Aclaris develops JAK inhibitors):
  • The global vitiligo treatment market size was valued at USD 1.74 billion in 2024 and is projected to grow to USD 2.38 billion by 2032.

Aclaris Therapeutics (ACRS) is a clinical-stage biopharmaceutical company with several key drivers expected to contribute to future revenue growth over the next 2-3 years, primarily through the advancement and potential commercialization of its pipeline assets and strategic partnerships:

1. Advancement of ATI-2138 into later-stage trials and new indications: Aclaris reported positive Phase 2a data for ATI-2138, an ITK/JAK3 inhibitor, in atopic dermatitis in July 2025. The company plans to initiate Phase 2 trials for ATI-2138 in additional immuno-inflammatory indications, such as lichen planus, scarring alopecias, and alopecia areata, in the first half of 2026. Successful progression through these clinical stages and potential expansion into multiple indications would significantly broaden the drug's market potential.
2. Progress of Bosakitug (ATI-045) in Atopic Dermatitis and Respiratory Conditions: ATI-045, an anti-TSLP monoclonal antibody, is currently in a Phase 2 trial for moderate-to-severe atopic dermatitis, with top-line results anticipated in the second half of 2026. Furthermore, Aclaris's partner BioSheng has three respiratory studies ongoing in China, including two Phase 3 studies in chronic rhinosinusitis (CRS) and severe asthma, and a Phase 2 study in COPD. While global development in respiratory indications is contingent on partnerships, positive outcomes from these trials and securing partnerships could lead to future revenue streams.
3. Development of ATI-052 for Asthma and Atopic Dermatitis: Aclaris initiated a Phase 1a/1b program for ATI-052, a bispecific anti-TSLP/IL-4R antibody, in June 2025. The company expects to initiate Phase 1b proof-of-concept trials for ATI-052 in both asthma and atopic dermatitis in the first half of 2026, with top-line results expected in the second half of 2026. Successful development of this potential best-in-class bispecific antibody could open up new significant market opportunities.
4. Introduction of Next-Generation ITK-Selective Inhibitors: Aclaris is actively engaged in preclinical work to develop next-generation ITK-selective inhibitors with extended half-lives and enhanced potency. The company anticipates filing Investigational New Drug (IND) applications for these new compounds starting in 2026. These new product candidates could further strengthen Aclaris's pipeline and offer additional therapeutic options in immuno-inflammatory diseases, contributing to long-term revenue growth.

Share Issuances

• Aclaris Therapeutics announced an underwritten public offering in January 2021, generating approximately $96.0 million in gross proceeds from the sale of 5,483,714 shares of common stock at $17.50 per share.
• In November 2024, the company secured approximately $80 million in gross proceeds through a private placement of 35,555,555 shares of common stock at $2.25 per share.
• Stockholders approved an amendment in June 2025 to increase the authorized common stock shares from 200 million to 400 million.

Inbound Investments

• In November 2024, Aclaris Therapeutics raised approximately $80 million through a private placement of common stock, with participation from investors including Vivo Capital, Forge Life Science Partners, and RA Capital Management.

Outbound Investments

• Aclaris Therapeutics acquired Confluence Life Sciences.
• In July 2024, the company sold a portion of its Eli Lilly royalties to OCM IP Healthcare Portfolio IP, an investment vehicle for Ontario Municipal Employees Retirement System (OMERS).

Capital Expenditures

• Projected capital expenditures are $5 million for 2025 and 2026, and $6 million annually from 2027 to 2029.
• The company's cash, cash equivalents, and marketable securities are expected to fund its operations, including capital expenditures, into the second half of 2028.
• Increased research and development (R&D) expenses, related to clinical development activities and product candidate manufacturing, have been a primary factor in the decrease of cash reserves.